3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Kidney Neoplasms
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Renal Insufficiency
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer
1
Liver Neoplasms
1
High-Risk Localized Prostate Cancer
1
Genital Neoplasms, Male
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Anemia
1
Interventions
enzalutamide
3
testosterone 17 beta-cypionate
2
darolutamide
2
abiraterone
2
Docetaxel
2
Androgen Antagonists
2
sipuleucel-T
1
pamiparib
1
olaparib
1
lactitol
1
fluciclovine F-18
1
enfortumab vedotin
1
cabazitaxel
1
avelumab
1
Standard of Care
1
Selegiline
1
Prednisolone
1
Pluvicto
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Castration-resistant Prostate Cancer
×
Pluvicto
×
Clear all
NCT06866938
2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2
Recruiting
58 enrolled